Nicox : Half-year liquidity contract statement with Kepler Cheuvreux as of December 31, 2023
January 08 2024 - 12:30AM
Nicox : Half-year liquidity contract statement with Kepler
Cheuvreux as of December 31, 2023
|
Press Release |
|
Nicox : Half-year liquidity contract statement with Kepler
Cheuvreux as of December 31, 2023 |
January 8, 2024 – release at 7:30 am CETSophia Antipolis,
France
Under the liquidity contract entered into between NICOX and
Kepler Cheuvreux, the following resources appeared on the liquidity
account on December 31st, 2023:
- 311,067 shares
- € 8,541.77
- Number of executions on buy side on semester: 92
- Number of executions on sell side on semester: 68
- Traded volume on buy side on semester: 27,902 shares for €
11,261.43
- Traded volume on sell side on semester: 21,402 shares for €
9,043.82
As a reminder:
- the following resources appeared on
the last half year statement on June 30, 2023 on the liquidity
account:
- 304,567 shares
- € 10,640.56
- Number of executions on buy side on semester: 128
- Number of executions on sell side on semester: 111
- Traded volume on buy side on semester: 74,584 shares for €
62,919.32
- Traded volume on sell side on semester: 58,982 shares for €
51,368.57
- the following
resources appeared on the liquidity account when the activity
started:
The implementation of this report is carried out
in accordance with AMF Decision N°2021-01 of June 22nd, 2021
renewing the implementation of liquidity contracts for shares as an
accepted market practice.
On January 3, 2024, Nicox announced the
termination of the liquidity contract dated August 3rd, 2020
entered into with Kepler Cheuvreux, effective as of January 1st,
2024.
Nicox Corporate Status
Update
The Company is currently funded until the end of
June 2024, exclusively on the basis of the development of NCX 470.
The Company is pursuing licensing discussions which could extend
the cash runway. In parallel, the Company is exploring multiple
strategic options and is also discussing with its creditors to
restructure its debt.
| |
Buy Side |
|
Sell Side |
| |
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Total |
92 |
27,902 |
11,261.43 |
|
68 |
21,402 |
9,043.82 |
|
03/07/2023 |
1 |
300 |
141.00 |
|
- |
- |
- |
|
07/07/2023 |
4 |
1,200 |
540.00 |
|
- |
- |
- |
|
10/07/2023 |
10 |
3,000 |
1,350.00 |
|
8 |
2,400 |
1,224.00 |
|
07/08/2023 |
2 |
300 |
126.00 |
|
- |
- |
- |
|
22/08/2023 |
1 |
1,000 |
430.00 |
|
- |
- |
- |
|
23/08/2023 |
6 |
1,000 |
440.00 |
|
1 |
300 |
132.00 |
|
24/08/2023 |
3 |
1,000 |
440.00 |
|
- |
- |
- |
|
25/08/2023 |
2 |
500 |
220.00 |
|
- |
- |
- |
|
28/08/2023 |
1 |
235 |
101.05 |
|
- |
- |
- |
|
29/08/2023 |
1 |
765 |
328.95 |
|
- |
- |
- |
|
01/09/2023 |
- |
- |
- |
|
1 |
1,000 |
440.00 |
|
14/09/2023 |
1 |
1,000 |
420.00 |
|
- |
- |
- |
|
20/09/2023 |
1 |
1 |
0.42 |
|
1 |
1 |
0.42 |
|
26/09/2023 |
2 |
301 |
123.41 |
|
1 |
1 |
0.42 |
|
04/10/2023 |
2 |
300 |
120.00 |
|
- |
- |
- |
|
05/10/2023 |
5 |
2,000 |
740.00 |
|
- |
- |
- |
|
09/10/2023 |
- |
- |
- |
|
2 |
300 |
114.00 |
|
10/10/2023 |
1 |
300 |
108.00 |
|
- |
- |
- |
|
12/10/2023 |
- |
- |
- |
|
1 |
1 |
0.40 |
|
17/10/2023 |
1 |
100 |
36.00 |
|
1 |
500 |
185.00 |
|
25/10/2023 |
2 |
1,000 |
330.00 |
|
- |
- |
- |
|
26/10/2023 |
5 |
1,455 |
436.50 |
|
2 |
500 |
170.00 |
|
27/10/2023 |
1 |
300 |
93.00 |
|
2 |
300 |
99.00 |
|
30/10/2023 |
1 |
445 |
133.50 |
|
- |
- |
- |
|
31/10/2023 |
- |
- |
- |
|
5 |
1,700 |
595.00 |
|
01/11/2023 |
- |
- |
- |
|
12 |
3,799 |
1,595.58 |
|
02/11/2023 |
- |
- |
- |
|
1 |
300 |
144.00 |
|
03/11/2023 |
- |
- |
- |
|
1 |
300 |
141.00 |
|
06/11/2023 |
1 |
300 |
138.00 |
|
- |
- |
- |
|
07/11/2023 |
1 |
300 |
132.00 |
|
- |
- |
- |
|
08/11/2023 |
- |
- |
- |
|
1 |
300 |
141.00 |
|
|
Buy Side |
|
Sell Side |
|
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
Number of executions |
Number of shares |
Traded volume in EUR |
|
09/11/2023 |
2 |
300 |
132.00 |
|
- |
- |
- |
|
13/11/2023 |
6 |
2,200 |
946.00 |
|
- |
- |
- |
|
14/11/2023 |
2 |
300 |
126.00 |
|
2 |
300 |
129.00 |
|
15/11/2023 |
3 |
900 |
369.00 |
|
- |
- |
- |
|
16/11/2023 |
- |
- |
- |
|
3 |
900 |
378.00 |
|
17/11/2023 |
1 |
300 |
120.00 |
|
- |
- |
- |
|
23/11/2023 |
1 |
500 |
205.00 |
|
- |
- |
- |
|
24/11/2023 |
1 |
300 |
120.00 |
|
- |
- |
- |
|
27/11/2023 |
6 |
1,560 |
608.40 |
|
- |
- |
- |
|
28/11/2023 |
3 |
500 |
195.00 |
|
4 |
1,000 |
400.00 |
|
29/11/2023 |
1 |
500 |
195.00 |
|
- |
- |
- |
|
01/12/2023 |
1 |
440 |
167.20 |
|
- |
- |
- |
|
04/12/2023 |
- |
- |
- |
|
1 |
500 |
200.00 |
|
05/12/2023 |
3 |
500 |
190.00 |
|
- |
- |
- |
|
06/12/2023 |
1 |
500 |
185.00 |
|
1 |
500 |
190.00 |
|
08/12/2023 |
- |
- |
- |
|
2 |
500 |
195.00 |
|
12/12/2023 |
1 |
500 |
190.00 |
|
- |
- |
- |
|
18/12/2023 |
- |
- |
- |
|
4 |
500 |
195.00 |
|
19/12/2023 |
4 |
1,000 |
390.00 |
|
- |
- |
- |
|
21/12/2023 |
1 |
500 |
195.00 |
|
- |
- |
- |
|
22/12/2023 |
- |
- |
- |
|
7 |
3,500 |
1,505.00 |
|
28/12/2023 |
- |
- |
- |
|
1 |
500 |
210.00 |
|
29/12/2023 |
- |
- |
- |
|
3 |
1,500 |
660.00 |
|
About Nicox |
|
Nicox SA is an international ophthalmology company developing
innovative solutions to help maintain vision and improve ocular
health. Nicox’s lead program in clinical development is NCX 470, a
novel nitric oxide-donating bimatoprost eye drop, for lowering
intraocular pressure in patients with open-angle glaucoma or ocular
hypertension. Nicox generates revenue from VYZULTA® in glaucoma,
licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in
allergic conjunctivitis, licensed in multiple geographies,
including to Harrow, Inc. in the U.S., and Ocumension Therapeutics
in the Chinese and in the majority of Southeast Asian
markets.Nicox, headquartered in Sophia Antipolis, France, is listed
on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the
CAC Healthcare index.For more information www.nicox.com. |
|
Analyst coverage |
|
Bryan, Garnier & Co
Eric
Yoo Paris,
FranceH.C. Wainwright &
Co Yi
Chen New York,
U.S. |
|
|
The views expressed by analysts in their coverage of Nicox are
those of the author and do not reflect the views of Nicox.
Additionally, the information contained in their reports may not be
correct or current. Nicox disavows any obligation to correct or to
update the information contained in analyst reports. |
|
Contacts |
|
|
NicoxGavin SpencerExecutive Vice President, Chief
Business Officer& Head of Corporate Development T +33 (0)4 97
24 53 00communications@nicox.com |
|
|
Forward-Looking Statements |
|
The information contained in this document may be modified without
prior notice. This information includes forward-looking statements.
Such forward-looking statements are not guarantees of future
performance. These statements are based on current expectations or
beliefs of the management of Nicox S.A. and are subject to a number
of factors and uncertainties that could cause actual results to
differ materially from those described in the forward-looking
statements. Nicox S.A. and its affiliates, directors, officers,
employees, advisers or agents, do not undertake, nor do they have
any obligation, to provide updates or to revise any forward-looking
statements.Risks factors which are likely to have a material effect
on Nicox’s business are presented in section 2.7 of the “Rapport
Annuel 2022” and in section 4 of the “Rapport semestriel financier
et d’activité 2023” which are available on Nicox’s website
(www.nicox.com). |
|
Nicox SADrakkar 2 - Bât D2405 route des
Dolines06560 Valbonne, FranceT +33 (0)4 97 24 53 00F +33 (0)4 97 24
53 99 |
- EN_KeplerHalfYearlyReportingDec312023_PR20240108
Nicox (LSE:0RCQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nicox (LSE:0RCQ)
Historical Stock Chart
From Apr 2023 to Apr 2024
